Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MK-1084 alone and with cetuximab in KRAS G12C-mutant advanced solid tumors
CTR20260175Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of calderasib, cetuximab in Nonhematologic neoplasms, cancer, sponsored by Merck & Co.. Started Apr 2026; status: active.
02
Drugs
calderasibcetuximab
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on CTR20260175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260175.